Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICCOLO trial in advanced colorectal cancer
ISRCTN93248876Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Mar 2006
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of irinotecan, panitumumab and cyclosporine in colorectal cancer (CRC) (4 arms), sponsored by University of Leeds. Primary endpoints: Progression-free at 12 weeks and Overall survival. Started Mar 2006; status: completed.
02
Drugs
irinotecanpanitumumabcyclosporine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN93248876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93248876.